Palisade Bio (PALI) Non-Current Debt (2013 - 2021)

Palisade Bio (PALI) posted quarterly Non-Current Debt of $94000.0 for Q4 2020, down 96.3% quarter-over-quarter from $2.5 million in Q1 2017.

Palisade Bio (PALI) Non-Current Debt (2013 - 2021) Analysis & Trends

Palisade Bio (PALI) has reported Non-Current Debt for 6 consecutive years, with $94000.0 the latest figure, recorded in Q4 2020.

In Q4 2020, Non-Current Debt changed N/A year-over-year to $94000.0; the TTM figure through Dec 2020 stood at $94000.0 (changed N/A YoY), while the FY2020 annual figure was $94000.0, changed N/A from the prior year.
Non-Current Debt declined to $94000.0 in Q4 2020 per PALI's latest filing, from $2.5 million in the prior quarter.
Across five years, Non-Current Debt topped out at $3.8 million in Q2 2016 and bottomed at $94000.0 in Q4 2020.
Historically, Non-Current Debt has averaged $2.7 million across 3 years, with a median of $3.2 million in 2016.
On a YoY basis, Non-Current Debt climbed as much as 11.33% in 2016 and fell as far as 63.39% in 2016.
Palisade Bio's Non-Current Debt stood at $3.8 million in 2016, then slumped by 32.47% to $2.5 million in 2017, then sank by 96.3% to $94000.0 in 2020.
Business Quant data shows PALI's Non-Current Debt at $94000.0 in Q4 2020, $2.5 million in Q1 2017, and $3.8 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Palisade Bio	372.94 Mn	247.74 Mn	-	-

Download Data